TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1827096

Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg twice daily)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Roxithromycin (150 mg twice daily)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Roxithromycin
Number of subjects: 77
Study: 6752799

Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Age 60 years or older
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Younger individuals
Number of subjects: 500
Study: 30979666

Group type: EXPERIMENTAL
Intervention: Psychosocial health promotion intervention (manual‐based multi‐component health promotion program based on motivational interviewing and cognitive behavioral therapy)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Run-in period before the start of the active intervention
Number of subjects: 689
Study: 27496630

Group type: EXPERIMENTAL
Intervention: Conservative transfusion strategy (RBC transfusion for hemoglobin < 7.0 g/dL for biventricular repairs or < 9.0 g/dL for palliative procedures plus clinical indication)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (RBC transfusion for hemoglobin < 9.5 g/dL for biventricular repairs or < 12 g/dL for palliative procedures regardless of clinical indication)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Conservative transfusion strategy
Number of subjects: 162
Study: 26561623

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2.4 g/d) for 4 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2.4 g/d) for 4 weeks + aspirin (300 mg/d) during the last 7 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (healthy matched subjects)
Number of subjects: 43
Study: 23751381

Group type: EXPERIMENTAL
Intervention: General anesthesia (n = 35)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Spinal anesthesia (n = 37)
Number of subjects: 72
Study: 21216507

Group type: EXPERIMENTAL
Intervention: 1 mg of methylcobalamin and 5 mg of folic acid once daily for 24 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo once daily for 24 months
Number of subjects: 140
Study: 19168870

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 813
Study: 17526862

Group type: EXPERIMENTAL
Intervention: G-CSF+ group (ATG, CyA, and G-CSF)
Number of subjects: 101

Group type: COMPARATOR
Intervention: G-CSF- group (ATG and CyA)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: G-CSF+ group
Number of subjects: 101

Group type: COMPARATOR
Intervention: G-CSF- group
Number of subjects: 101
Study: 15446640

Group type: EXPERIMENTAL
Intervention: Indoor balance training on a balance board, wearing ski boots, for 20 min. every second day in the afternoon
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ski lessons only for two weeks, 2 to 4 hours daily
Number of subjects: 30
Study: 11404668

Group type: EXPERIMENTAL
Intervention: Total-body resistance training (TP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Upper-body resistance training (UP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Total-body resistance training (TH)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Upper-body resistance training (UH)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Field training (FLD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Aerobic training (AER)
Number of subjects: 68
Study: 9536157

Group type: EXPERIMENTAL
Intervention: Antioxidant supplements (15 mg beta‐carotene, 75 mg vitamin E, and 650 mg vitamin C) once a day for three months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 26
Study: 7625474

Group type: EXPERIMENTAL
Intervention: 4 mg/day of haloperidol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg/day of haloperidol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40 mg/day of haloperidol
Number of subjects: 24
Study: 2186655

Group type: EXPERIMENTAL
Intervention: Oral ketamine 10 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular morphine 0.1 mg/kg
Number of subjects: 40
Study: 371540

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 2581

Group type: COMPARATOR
Intervention: Cyclacillin
Number of subjects: 2581
Study: 31754300

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 41
Study: 27112775

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 281
Study: 26372487

Group type: EXPERIMENTAL
Intervention: 4-week intensive fluconazole treatment for CrAg-positive patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: No treatment (CrAg-negative patients)
Number of subjects: 72
Study: 23831139

Group type: EXPERIMENTAL
Intervention: Exposure to relational aggression
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Exposure to physical aggression
Number of subjects: 150

Group type: COMPARATOR
Intervention: Exposure to no aggression (control group)
Number of subjects: 150
Study: 20393824

Group type: EXPERIMENTAL
Intervention: Colorectal cancer education video
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (another program in American Sign Language)
Number of subjects: 144
Study: 19229431

Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Deep breathing exercises
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Deep breathing exercises + Positive expiratory pressure
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Positive airway pressure + Inspiratory resistance
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure breathing
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure
Number of subjects: 997
Study: 16875796

Group type: EXPERIMENTAL
Intervention: Brief patient decision aid (pDA)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Control group (questionnaire alone)
Number of subjects: 990
Study: 14669315

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for 12 months
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (treatment-naïve)
Number of subjects: 131
Study: 11074989

Group type: EXPERIMENTAL
Intervention: Semiocclusive, heated dressing applied to 15 Stage III and IV pressure ulcers for 4.5 hours, Monday through Friday, for 4 consecutive weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard wound care plus heated dressing.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard wound care (control group).
Number of subjects: 20
Study: 8842833

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 1495849

Group type: EXPERIMENTAL
Intervention: Oral ribosomal vaccine D53
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Long-term oral ribosomal vaccine D53
Number of subjects: 17
Study: 6716521

Group type: EXPERIMENTAL
Intervention: 10-gauge Angiocath and 8 Fr pulmonary artery introducer catheter with large-bore intravenous tubing (5.0 mm I.D.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intravenous tubing (3.2 mm I.D.)
Number of subjects: 0
Study: 31450964

Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experiences (ACEs)
Number of subjects: 12229

Group type: EXPERIMENTAL
Intervention: ACEs
Number of subjects: 12229
Study: 28683845

Group type: EXPERIMENTAL
Intervention: Co‐Phenylcaine Zest
Number of subjects: 86

Group type: COMPARATOR
Intervention: Co‐Phenylcaine Forte
Number of subjects: 86
Study: 26306785

Group type: EXPERIMENTAL
Intervention: edus2
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 33
Study: 24615728

Group type: EXPERIMENTAL
Intervention: Standard breakfast
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fasting conditions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nutritional protein-rich drink
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Standard breakfast and nutritional protein-rich drink
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 11
Study: 23226426

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy + Cetuximab or Panitumumab
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy + Cetuximab
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy + Anti-EGFR drugs
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Oxaliplatin-based chemotherapy
Number of subjects: 1270
Study: 19962799

Group type: EXPERIMENTAL
Intervention: Breast-fed infants exposed to caraway flavour via mother's milk (n=20)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Breast-fed infants not exposed to caraway flavour (non-exposed group, n=20)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Formula-fed infants whose mothers consumed caraway-flavoured food (n=8)
Number of subjects: 48
Study: 17432692

Group type: EXPERIMENTAL
Intervention: Qingjin Runfei Decoction (QRD) combined with hormone and antibiotic
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hormone and antibiotic
Number of subjects: 104
Study: 17539738

Group type: EXPERIMENTAL
Intervention: Total volumetric BMD (vBMD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cortical thickness (geometry)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Trabecular number (microstructure)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Axial rigidity (strength)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Factor-of-risk (fall load/microFE failure load)
Number of subjects: 36
Study: 15610365

Group type: EXPERIMENTAL
Intervention: Active omega-3 supplemented group (daily tuna fish oil supplement and omega-3-rich margarines and cooking oils)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Control group (placebo supplement with polyunsaturated margarines and cooking oils)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Active omega-3 supplemented group
Number of subjects: 376
Study: 10845823

Group type: EXPERIMENTAL
Intervention: High dialysate calcium concentration (HdCa; 1.75 mmol/L)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low dialysate calcium concentration (LdCa; 1.25 mmol/L)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Switching from HdCa to LdCa treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both LdCa and HdCa treatment groups
Number of subjects: 19
Study: 9354201

Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy (40 mg once daily, amoxycillin 1 g b.d. for 2 weeks, metronidazole 400 mg t.d.s. for the first week)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Omeprazole dual therapy (40 mg once daily, amoxycillin 1 g b.d. for 2 weeks, placebo during the first week)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: All patients treated analysis for omeprazole triple therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: All patients treated analysis for omeprazole dual therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Follow-up of H. pylori-negative patients
Number of subjects: 183

Group type: COMPARATOR
Intervention: Consultations, investigations, and prescriptions relating to upper gastrointestinal symptoms
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 183
Study: 8415473

Group type: EXPERIMENTAL
Intervention: Tianeptine (T) 37.5 mg/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: Maprotiline (M) 75 mg/day
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tianeptine (T) with Hormone Replacement Therapy (HRT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Maprotiline (M)
Number of subjects: 83
Study: 3545686

Group type: EXPERIMENTAL
Intervention: Pindolol (10 to 20 mg per day)
Number of subjects: 7324

Group type: EXPERIMENTAL
Intervention: Pindolol alone or in combination with a diuretic
Number of subjects: 7324

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 7324
Study: 30017404

Group type: EXPERIMENTAL
Intervention: MRI with systematic and targeted biopsy using the Artemis fusion targeting system
Number of subjects: 273

Group type: COMPARATOR
Intervention: 12-core systematic biopsy
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Targeted biopsy alone (MRI arm)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Systematic biopsy (MRI arm)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Targeted biopsy (MRI arm)
Number of subjects: 273
Study: 29031743

Group type: EXPERIMENTAL
Intervention: JZP-110
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 26215435

Group type: EXPERIMENTAL
Intervention: Continuing pioglitazone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Discontinuing pioglitazone
Number of subjects: 77
Study: 24413697

Group type: EXPERIMENTAL
Intervention: Post-study caffeine administration
Number of subjects: 0
Study: 22803404

Group type: EXPERIMENTAL
Intervention: Moderate to severe vesicles
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TGF beta1 levels in nasal polyps (1-3 weeks group and 6-8 weeks group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: VEGF levels in nasal polyps (6-8 weeks group)
Number of subjects: 40
Study: 19448528

Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pills (OCPs)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Depomedroxyprogesterone Acetate (DMPA)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Intrauterine Device (IUD)
Number of subjects: 599
Study: 18036290

Group type: EXPERIMENTAL
Intervention: Propofol combined with low dose fentanyl (Group PF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Midazolam combined with low dose fentanyl (Group MF)
Number of subjects: 32
Study: 15465742

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11370993

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) applied to the right or left frontal cortex at 0.5 Hz, 130% of motor threshold, 60 stimuli
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo condition (TMS applied to the occipital cortex)
Number of subjects: 18
Study: 9734883

Group type: EXPERIMENTAL
Intervention: Portal-vein infusion (PVI) of fluorouracil (500 mg/m2) plus heparin (5000 IU daily for 7 days)
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Portal-vein infusion (PVI) of fluorouracil
Number of subjects: 1235
Study: 8111606

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (16 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Albuterol (800 micrograms/day)
Number of subjects: 29
Study: 3416961

Group type: EXPERIMENTAL
Intervention: Continuous speech, music, or intermittent noise delivered to the left ear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent noise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous noise fed to the left ear
Number of subjects: 0
Study: 31466923

Group type: EXPERIMENTAL
Intervention: Spiritual care program (three sessions conducted by a nurse, clergy, and patient's companion before, during, and after dressing change)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 68
Study: 28209624

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 26032655

Group type: EXPERIMENTAL
Intervention: Liraglutide (LIRA) 1.2 mg QD s.c.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Roflumilast (ROF) 500 mcg QD
Number of subjects: 45

Group type: COMPARATOR
Intervention: Metformin (MET) 1000 mg BID
Number of subjects: 45
Study: 23609792

Group type: EXPERIMENTAL
Intervention: Fructose combined with fat (0.5 g/kg body weight fructose, 1 g/kg OFTT cream as fat)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fat only (1 g/kg OFTT cream)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Glucose (0.5 g/kg body weight)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fructose (0.5 g/kg body weight)
Number of subjects: 9
Study: 21746729

Group type: EXPERIMENTAL
Intervention: Moderate-oxygen group (oxygen titration starting from 100%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-oxygen group (static concentration of 100% oxygen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-oxygen group (starting from 21% oxygen)
Number of subjects: 0
Study: 19166298

Group type: EXPERIMENTAL
Intervention: Purple carrot juice containing 76 micromol (65 mg) of total anthocyanins
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Purple carrot juice containing 228 micromol (194 mg) of total anthocyanins
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Purple carrot juice containing 380 micromol (323 mg) of total anthocyanins
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acylated anthocyanins in purple carrot juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nonacylated anthocyanins in purple carrot juice
Number of subjects: 10
Study: 16700404

Group type: EXPERIMENTAL
Intervention: Liquid multi-vitamin/mineral supplement
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16146036

Group type: EXPERIMENTAL
Intervention: Laser biostimulation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conservative treatment only
Number of subjects: 6
Study: 14559928

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 150 mg DHEA, 300 mg androstenedione, 750 mg Tribulus terrestris, 625 mg chrysin, 300 mg indole‐3‐carbinol, and 540 mg saw palmetto
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing DHEA, androstenedione and herbal extracts
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11203865

Group type: EXPERIMENTAL
Intervention: Tetric Ceram
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hydrophobic materials
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hydrophilic materials
Number of subjects: 6
Study: 9256120

Group type: EXPERIMENTAL
Intervention: Cranial radiation (CRT) and intrathecal methotrexate (IT MTX)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Extended triple intrathecal therapy (TIT)
Number of subjects: 192
Study: 1554839

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (≤2 g IM daily for at least 2 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Doxycycline for 4 weeks plus streptomycin for 2 weeks
Number of subjects: 18
Study: 3547993

Group type: EXPERIMENTAL
Intervention: OM-8930
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 30282375

Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 26633582

Group type: EXPERIMENTAL
Intervention: Active gas aspiration
Number of subjects: 74

Group type: COMPARATOR
Intervention: Simple gas evacuation (control)
Number of subjects: 74
Study: 24977497

Group type: EXPERIMENTAL
Intervention: Intensive medical management
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 390
Study: 22268591

Group type: COMPARATOR
Intervention: Intranasal midazolam (0.2 mg·kg(‐1))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg·kg(‐1))
Number of subjects: 90
Study: 20038617

Group type: EXPERIMENTAL
Intervention: Amdoxovir (AMDX) at 500 mg b.i.d. + ZDV at 200 mg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amdoxovir (AMDX) at 500 mg b.i.d. + ZDV at 300 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) at 200 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) at 300 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Amdoxovir (AMDX) at 500 mg b.i.d. + placebo
Number of subjects: 24
Study: 18686421

Group type: EXPERIMENTAL
Intervention: Different devices to measure temperature
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16408674

Group type: COMPARATOR
Intervention: Fixed combination timolol‐dorzolamide
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 38
Study: 12716811

Group type: EXPERIMENTAL
Intervention: Electronic reminder plus a letter summarizing the beneficial effects of antiplatelet drugs
Number of subjects: 15343

Group type: COMPARATOR
Intervention: Control group received only the letter
Number of subjects: 15343
Study: 10609972

Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alcohol placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Soda
Number of subjects: 24
Study: 7581058

Group type: EXPERIMENTAL
Intervention: 10 mg Loratadine daily for 3-4 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Single dose of 30 mg Loratadine
Number of subjects: 6

Group type: COMPARATOR
Intervention: 10 mg Loratadine for 5 days
Number of subjects: 6
Study: 2008985

Group type: EXPERIMENTAL
Intervention: Ventilator circuit changes every 48 hours (Group 1)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No change in ventilator circuits (Group 2)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups were similar in terms of age, indication for and duration of ventilation, and severity of illness.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia defined by specific criteria
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Bacterial colonization assessed every 48 hours
Number of subjects: 73
Study: 6123332

Group type: EXPERIMENTAL
Intervention: Estazolam (2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10